Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4304914 | 0.86 | CTSK (0.37) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL4307673 | 0.86 | CTSK (0.37) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL4301341 | 0.83 | CTSK (0.35) | CTSKMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL4304666 | 0.80 | CHRM2 (0.37) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL10137647 | 0.78 | NR1H2 (0.34) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL14583034 | 0.78 | NR1H2 (0.34) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL13305792 | 0.77 | HSD17B10 (0.36) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL30536042 | 0.77 | HSD17B10 (0.36) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL4307305 | 0.76 | NR1H2 (0.35) | ALDH1A1NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL30685043 | 0.72 | DPP4 (0.44) | CTSKMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281331-A1 | METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2014648-A1 | PROCESS FOR PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDUCT SALT THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281331-A1 | METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF | C9, NPPA, ADH1C | CTSK 3721/4885MEN1 895/4885ALDH1A1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.